To identify the cancer types that could potentially benefit from covalent protein-degrading EZH2 inhibitor, IHMT-337, we first analyzed the TCGA database and results revealed that EZH2 is highly expressed in a variety of cancer types, especially breast cancer, which less dependent on PRC2 complex-related EZH2 methyltransferase activity. This evidence concerns the gene EZH2 and breast carcinoma.